Cancer of the rectum poses a complex therapeutic challenge because of its proximity to adjacent organs and anal sphincters. The addition of radiotherapy before surgical resection has been shown to confer good survival rates while preserving sphincter function. Nevertheless, radiation is associated with significant side effects. On the basis of our previous work showing that herpes simplex virus type-1 (HSV-1) preferentially infects human colon cancer, we set out to examine the oncolytic effect of HSV-1 on orthotopic rectal tumors in mice. Two vectors were compared for oncolytic activity, HSV-1(Gb) with wild-type replication and an attenuated HSV-1 vector (HSV-G47D). Intratumoral injection of HSV-1(Gb) and HSV-G47D resulted in a significant reduction or disappearance of the tumors and increased survival of mice. Although the use of HSV-1(Gb) was associated with systemic toxicity, HSV-G47D appears to possess a selective oncolytic activity. Moreover, infection with HSV-G47D resulted in the activation of the doublestranded RNA-dependent protein kinase (PKR) pathway. A significant improvement in viral replication and the antitumor effect was observed when the PKR inhibitor 2-aminopurine was coadministered with HSV-G47D to the tumor. In conclusion, the efficacy of local delivery of HSV-G47D combined with a specific chemical inhibitor of antiviral activity points to a novel therapeutic modality for rectal cancer and other solid tumors.
Introduction
Adenocarcinoma of the rectum annually affects more than 40 000 patients in the United States. Although rectal cancer is biologically similar to colon cancer, the anatomic complexity of the pelvis and the proximity to the anal sphincters makes therapy for this disease considerably more complicated. 1 A main treatment goal in this disease is to reduce the inherently high rate of local tumor recurrence following surgical resection while trying to preserve sexual and sphincter functions. A major advancement toward these goals has been the realization that preoperative, neoadjuvant external beam radiation to the rectum, frequently combined with chemotherapy, can decrease the tumor mass significantly, thus permitting a less extensive subsequent surgical resection. The radiation-induced pathological downstaging has also been shown to significantly reduce the rate of local tumor recurrence and to improve patient survival. However, this form of treatment is associated with substantial short-and long-term radiation-induced bowel injury that may cause debilitating symptoms. Also, preoperative radiotherapy requires daily radiation for a period of several weeks resulting in patient discomfort and delay in the subsequent definitive surgical treatment. 2 Therefore, a therapeutic strategy employing direct gene delivery into the rectal tumor may offer a novel neoadjuvant modality that addresses the disadvantages of preoperative radiation. Because rectal cancer can be accessed with relative ease through the anus, it represents an ideal target for direct vector injection. To offer a rational and safe alternative to radiation, local gene transfer should lead to a rapid antitumor effect with minimal systemic side effects. Gene therapy approaches for colon cancer have been studied before, mainly in cell culture and in murine models with subcutaneous (s.c.) tumors or liver metastases. 3, 4 Most involve viral-based strategies that utilize replication-defective viruses as vectors that carry therapeutic genes, including cytokines, prodrugs and tumor suppressors. 4 An alternative approach is to use replication-competent viruses that directly kill tumor cells. To increase their antitumor effect and to reduce their virulence to normal tissues, we can genetically design replicating oncolytic viruses to infect and replicate preferentially in tumor cells. 5, 6 Despite an experimental effort in a variety of tumor models, vector types and routes of delivery, cancer gene therapy has yet to be translated into a clinically relevant therapeutic mode. This stems mainly from biosafety concerns and the incomplete tumor eradication achieved by viral-based methods. 7 Because the goal in applying a virus-mediated treatment for rectal cancer is to reduce tumor size rather than to completely eradicate the tumor, gene transfer may be a realistic component in treating rectal cancer. We have recently shown, utilizing an ex vivo organ culture system, that herpes simplex virus type-1 (HSV-1) preferentially infects colon carcinoma compared to noncancerous tissues. We demonstrated that HSV-1 infects human and mouse colon carcinomas with high efficiency whereas the normal adjacent colonic mucosa is resistant to HSV-1 infection. In contrast, replication-deficient adenovirus infected both the cancer and normal mucosa tissues to the same extent. 8 We further demonstrated that the extracellular matrix components, mucin and collagen, which are more abundant in the normal colon compared to the colon cancer tissue, constitute barriers to normal colonic mucosa infection by HSV-1. The marked tropism of HSV-1 vectors to colon cancer suggested that it may be a promising vector to treat rectal cancer. We therefore set out to examine the tropism and oncolytic effect of HSV vectors in a novel, orthotopic rectal cancer model in mice. Two vectors were tested, oncolytic HSV-1 with a wildtype replication capacity and an attenuated oncolytic HSV-1 vector for enhanced safety and specificity. The feasibility and efficiency of HSV vectors in the present experimental model, which closely simulates the human condition, provides proof of concept for the clinical implementation of this strategy.
Results

HSV vectors preferentially infect human colon cancer
We have previously shown that HSV-1 preferentially infects ex vivo tissues derived from mouse and human colon cancer compared to the normal colon tissues. 8 We have further demonstrated that the extracellular matrix components, mucin and collagen, which are more abundant in the normal colon compared to the colon cancer tissue, constitute barriers to normal colonic mucosa infection by HSV-1. To determine whether this observation is unique to HSV, we compared the infectivity and tropism of non-herpes vectors in the same ex vivo human tissue culture system. To this end, thin slices of human colon and carcinoma tissues were infected at the same multiplicity with lentivirus (pseudotyped with VSV-G), adenovirus and HSV-1(Gb) all carrying the LacZ reporter gene. Figure 1a demonstrates that lentivirus and adenovirus infections are similar in the normal or cancerous tissues whereas HSV-1 preferentially infects the human colon cancer. In addition we examined the infectivity and tissue selectivity of HSV-1(Gb) and oncolytic HSV-G47D. Because of deletion of the g34.5 and ICP6 genes, HSV-G47D replicates preferentially in cancer cells while sparing neurons and other normal cells, and therefore would be safer for in vivo use. 9, 10 The histological specimen of the infected tissues presented in Figure 1b demonstrated that both HSV-1(Gb) and the attenuated HSV-G47D infected equally well the human colon carcinoma tissue while sparing the healthy colon. The efficiency of infection by HSV-1(Gb) and HSV-G47D, and their tropism to the colon carcinoma tissue suggest that they may be suitable vectors for colon carcinoma applications.
Establishment of an orthotopic rectal cancer model in mice
To test the efficacy of HSV vectors in a clinically relevant model, we established an orthotopic rectal cancer model in mice that mimics human rectal cancers better then the s.c. cancer model. A mouse colon carcinoma cell line CT26 was injected under the mucosa of the distal rectum of Balb/C mice. To follow tumor development in the mouse and to quantitate the response to viral therapy, we stably transfected CT26 cells with the luciferase (luc) gene. Tumor volume and spread in anesthetized animals were determined by real-time imaging of luciferase expression. Using this method, we detected rectal and s.c. tumors 8 and 15 days after tumor cell injection. Figure 1 Herpes simplex virus type-1 (HSV-1) preferentially infects human colon carcinoma tissues. (a) Human colon carcinoma or normal mucosa tissues were prepared for organ cultures as described in Materials and methods section. Infection was carried out for 48 h with lentivirus (2 Â 10 6 IU per well), adenovirus (2 Â 10 6 IU per well) and HSV-1(Gb) (2 Â 10 6 IU per well). The expression of b-Gal was analyzed 48 h after infection by X-Gal staining and photographed at Â 40 magnification. Results of a representative experiment with tissues of one out of the three patients examined are presented in (a). Blue staining represents infected cells and is indicated by the arrows. (b) Human normal colon and colon carcinoma organ culture tissues were infected with HSV-1(Gb) and HSV-G47D (2 Â 10 6 IU per well) as described in Materials and methods section. Organ cultures were stained with X-Gal at 24 h after infection and taken for paraffin section. Histological sections (5 mm) were prepared from normal and tumor tissues and counterstained with nuclear fast red (NFR). Blue spots represent infected cells and are indicated by arrows. Slides were photographed at Â 100 magnification.
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Tumor spread was predominantly local (Figures 2a  and b ). Tumor growth both orthotopic and s.c. was rapid leading to animal death within 15-25 days ( Figure 2c ). Next, we compared the pattern and rate of tumor progression between tumors developing after s.c. injection to orthotopic carcinoma after rectal injection. s.c. tumors developed more rapidly and spread more extensively under the skin compared to rectal tumors (Figure 2d ). This may explain the observed trend toward a more rapid tumor progression in animals harboring s.c. tumors compared to those with rectal tumors.
To verify that the tumors were indeed rectal rather than tumors arising under the anal skin, we killed animals after tumor development and subjected the tumors to histopathological analysis. This analysis clearly shows that the tumor tissue protrudes into the rectal mucosa, spreading radially to involve all the layers of the bowel, thus mimicking closely human tumors (Figure 2eI, II) .
The predictable local tumor growth pattern and rate, lack of metastases and availability of an accurate in vivo monitoring system of tumor progression, suggest that the model described here will be beneficial for studying different aspects of viral-based and other therapies for rectal cancer.
HSV delivery results in an efficient antitumor effect and increases mice survival
We first sought to determine the systemic toxicity of HSV-1(Gb) after intrarectal injection. The majority of the mice that were given more than 10 6 infection units (IU) of HSV-1(Gb) directly to the tumor died within 5-6 days, compared to control animals receiving phosphate-buffered saline (PBS) who did not suffer from any side effects (data not shown). To avoid the systemic toxicity of HSV-1(Gb), we developed a treatment protocol combining intratumoral HSV-1(Gb) injection with Ganciclovir (GCV) to halt viral replication. To allow initial limited viral expansion and tumor cell lysis, we gave GCV 3 days after HSV-1(Gb) delivery (day 13). HSV-1(Gb) was injected directly into the rectal tumor 10 days after tumor cell inoculation when the tumor was visible and reached a similar size in most mice (Figures 3a-c; 10 days) . The response to treatment was followed by in vivo imaging of luciferase expression in the tumor. In mice receiving a single injection of HSV-1(Gb) (5 Â 10 6 IU) followed by GCV treatment, there was an arrest in tumor growth when measured 7 days later, compared to mice injected with saline in which the tumor volume increased with time. The control mice had a significantly larger tumor size (4.9-fold) compared to the treated mice (Figure 3c ). Moreover, HSV-1(Gb) treatment significantly improved mice survival. All untreated mice did not survive beyond day 22, whereas 60% of the HSV-1(Gb)-treated mice survived more than 32 days at which time the mice were killed (Figure 3d ).
HSV-1(Gb) injection causes a selective apoptotic response in the tumors while sparing the adjacent normal colon
To determine the oncolytic mechanisms of HSV, we infected and analyzed organ cultures of tumor slices in situ for coexpression of activated Caspase-3, an apoptotic marker (red) and reporter gene GFP expression (green). Whole-mount slices were visualized under a confocal microscope, such that infected cells undergoing apoptosis stain yellow (Figure 4aIII ). The results show that tumor cell apoptosis occurred predominantly in the HSV-1(Gb)-infected cells (Figure 4aIII ). It should be noted that there was no significant bystander killing effect, most probably because the tumor organ cultures were not treated with GCV. We further analyzed this in vivo, using HSV combined with GCV. Orthotopic 
HSV-G47D treatment results in significantly enhanced tumor eradication without systemic side effects
As indicated above, although HSV-1(Gb) is quite specific to the tumor tissue, at high virus concentrations (10 7 IU) some spread to the adjacent normal colon was observed. To achieve a better safety profile, we next examined the activity of oncolytic HSV-G47D at high dose (5 Â 10 7 IU per mice), with and without GCV ( Figure 5 ). Treatment of tumors with HSV-G47D, without GCV, yielded efficient regression of the tumor and all treated animals survived past 21 days, whereas the control animals succumbed to the tumor by day 21 (Figures 5a and b ). There were no signs of tumor recurrence in mice that exhibited initial complete tumor eradication. Interestingly, the addition of GCV 3 days after of HSV-G47D injection, completely abolished the oncolytic effect (Figure 5b ). This suggests that continuous viral replication is required for the oncolytic activity.
Inhibition of the double-stranded RNA-dependent protein kinase enhances the oncolytic effect of HSV-G47D
The g34.5 gene, deleted in HSV-G47D, 9 inhibits the double-stranded RNA-dependent protein kinase (PKR) pathway, 11 a key component mediating host antiviral activity. 12 This may explain the low viral replication of HSV-G47D and other attenuated vectors in infected cells compared to wild-type HSV. 9 We therefore, hypothesized that inhibition of PKR in infected tumor cells would Figure 3 Herpes simplex virus (HSV) combined with Ganciclovir (GCV) treatment results in the inhibition of orthotopic colon carcinoma growth and increased mice survival. Mice were injected orthotopically with CT26/luc cells (2 Â 10 6 IU) as described in Materials and methods section. After 10 days, images were taken and mice were injected directly to the tumor with HSV-1(Gb) (5 Â 10 6 IU per 50 ml PBS, n ¼ 5) or with 50 ml PBS as control (n ¼ 4). At day 13, animals were injected i.p. with GCV (10 mg kg À1 ) twice daily for 14 days. Mice were imaged for luciferase activity at day 10 and 17 as described in Materials and methods section. Representative mice from each group (a) control and (b) HSV-1(Gb)+GCV treated. (c) Calculation of the average tumor size was carried out by analysis of CCD images as described in Materials and methods section. (d) Survival of the mice treated with HSV-1(Gb)+GCV and control mice was examined for 32 days. Asterisk (*) indicates that the survival of mice treated with a combination of HSV-1(Gb) and GCV was significantly enhanced in comparison to the control mice.
Selective oncolytic activity of herpes simplex virus to colon carcinoma D Kolodkin-Gal et al Figure 4 Combination of herpes simplex virus (HSV)-1(Gb) and Ganciclovir (GCV) treament causes extensive apoptotic response in the tumor tissue. (a) Mice were injected s.c. with CT26/luc cells (2 Â 10 6 IU). After 10 days, when tumor developed, mice were killed and the tumors tissues were prepared for organ culture and infected with HSV-1(Gb) (2 Â 10 6 IU per well). At 72 h after infection, the infected tissues were stained for immunofluorescence as described in Materials and methods section, with first antibody, anti-activated Caspase-3, and second antibody conjugated to Cy5. Positive apoptotic cells appear as red (I). Costaining of infected cells expressing green fluorescent protein (GFP) (II) and activated Caspase-3, red (I) are seen in yellow (III). The doubly stained yellow cells are indicated by white arrowheads. As control, tissues were stained without the first antibody (against activated Caspase-3) (IV). All immunofluorescence images were captured with a Zeiss 510 confocal microscope, magnification Â 300. (b) Mice were injected orthotopically with CT26/luc cells (2 Â 10 6 IU) as described in Materials and methods section. After 10 days, mice were injected directly to the tumor with HSV-1(Gb) (5 Â 10 6 IU per 50 ml PBS). At 72 h after infection, animals were treated by i.p. injection of GCV (10 mg kg Mice were injected orthotopically with colon carcinoma CT26/luc cells (2 Â 10 6 IU) as described in Materials and methods section. After 9 days, when tumors developed, mice were injected directly to the tumor with HSV-G47D (5 Â 10 7 IU per 100 ml PBS) or with 100 ml PBS as control. At 72 h after infection, animals were treated by i.p. injection of Ganciclovir (GCV) (10 mg kg À1 ) or phosphate-buffered saline (PBS) as indicated, twice daily. After 8, 14, 18 and 21 days, mice were imaged for luciferase activity as described in Materials and methods section. Representative mice from each group are presented (a). Calculation of tumor size was carried out by analysis of CCD images as described in Materials and methods section (b). Asterisks indicate that tumors treated with G47D was significantly decrease in size compared to tumors treated with PBS (Control), *Po0.05.
Selective oncolytic activity of herpes simplex virus to colon carcinoma D Kolodkin-Gal et al enhance viral replication and subsequently augment the oncolytic effect of attenuated vectors. To test this, we first measured the level of PKR activation, by western blot analysis of phosphorylated PKR, in the CT26 colon carcinoma cells after HSV-G47D or HSV-1(Gb) infection. Figure 6 shows a large increase in the level of PKR phosphorylation at 6 h after infection with HSV-G47D, whereas HSV-1(Gb) did not activate PKR above baseline, in line with a previous report. 13 When HSV-G47D-infected cells where treated with 2-aminopurine (2AP), a specific PKR inhibitor, 14,15 PKR activation was not observed as expected. On the basis of these results, we examined the effect of 2AP on the replication of HSV-G47D in mouse and human colon carcinoma cell lines. Cultured cells were infected at low multiplicity with and without 2AP and the titer of progeny virus was determined (Figures 7a and b) . PKR inhibition resulted in a significant increase of viral titer in both the mouse and human tumor cells (4.4-fold (Po0.05) and 5.9-fold (Po0.000001), respectively). Next, we examined the effect of 2AP on HSV-G47D replication and spread in an ex vivo organ culture system of mouse colon carcinoma (CT26). Treatment with 2AP dramatically enhances HSV-G47D replication (increase in blue X-Galpositive cells) to a level as high as the wild-type HSV (Figures 7c and d) .
To investigate the in vivo effects of concomitant treatment of 2AP and HSV-G47D, we induced rectal tumors in mice and treated them with a single injection of HSV-G47D delivered intratumorally with or without 2AP. Figure 8a demonstrates that addition of 2AP to HSV-G47D results in a 3.4-fold decrease in tumor volume compared to injection with HSV-G47D alone, at 5 days after initiation of treatment. In this experiment, the tumors were allowed to reach a bigger size before the combined 2AP and HSV-G47D treatment as compared with the experiments depicted in Figure 5 . This may explain the lower response to HSV-G47D alone, as observed in Figure 8 . There were no apparent signs of toxicity in the mice after coinjection of virus and drug. To examine the pattern of viral infection and dissemination in the orthotopic tumors in vivo, we prepared tissues for histology 3 days after injection of HSV-G47D, with and without 2AP (Figure 8b ). More extensive viral spread was evident in tumor tissues infected in vivo with HSV-G47D and 2AP, as compared to tumors treated with HSV-G47D alone. Virus spread was associated with enhanced tumor destruction as indicated by large necrotic areas (Figure 8b , red line encircling area of necrotic tissue). However, viral spread was restricted to the tumor as demonstrated by the lack of viral transgene expression in the adjacent normal colon, liver, lungs and brain (data no shown).
Taken together these data suggest that intratumoral administration of an oncolytic HSV combined with specific inhibition of the PKR pathway may offer a rational, effective treatment modality for cancer.
Discussion
Adenocarcinoma of the rectum is a common type of cancer occurring at the distal part of the colon. 1 Similar to other types of gastrointestinal cancers, rectal cancer originates from the colonic mucosa and spreads radially to subsequently involve all layers of the colon's wall, including regional lymph nodes and adjacent organs. Invasion of cancer cells into blood vessels may lead to development of distant metastases. The lower part of the rectum is situated in the pelvis in proximity to organs such as the urinary bladder, the prostate and nerves responsible for sexual function in men, and uterus and vagina in females. Therefore, advanced rectal tumors frequently require extensive surgery, including resection of these structures. In addition, a low-lying tumor may necessitate the killing of the anal sphincters causing the patient to suffer from permanent disability. This feature of rectal cancer and the relatively high incidence of local tumor recurrence despite extensive surgery have led to the addition of preoperative radiotherapy to the treatment protocol. The goal of radiation is to reduce tumor size and to enable a less extensive operation without compromising the chance for a cure. However, radiationinduced damage to normal surrounding organs is a serious limitation of such therapy. The need for a preoperative treatment modality with less side effects and the easily accessible location of rectal adenocarcinoma make this tumor an ideal candidate for local viral therapy. The orthotopic rectal cancer mouse model that we have developed provides an excellent platform to simulate the different aspects of viral therapy that may be encountered in humans. The local rather than metastatic model allows recapitulation of the human setting in terms of tumor microenvironment and anatomical constraints. The mouse model also allows studying the technical obstacles related to optimal delivery of the To overcome the limited intratumoral spread of virus after local injection, which has been shown to significantly hamper the efficacy of several oncolytic vectors, 16 we elected to utilize a replicating oncolytic virus HSV-1 in our model. This virus is highly cytopathic and several anti-herpetic drugs are available as a safeguard against unfavorable replication of the virus. 5 We have previously demonstrated, in an ex vivo model of human-derived organ cultures, that HSV-1 specifically infected the colon cancer tissue while the normal colon tissue was resistant to infection, due to the mucus layer and extracellular matrix proteins. 8 Such a selective viral/ tumor tropism could not be shown with adeno and lenti viral vectors (Figure 1 ). These features prompted us to test the efficacy of HSV as a potential therapy in an orthotopic model of colorectal carcinoma. Indeed, direct delivery of HSV-1(Gb) into the rectal tumor resulted in tumor cell infection accompanied by extensive apoptosis. There was no apparent infection or damage at the adjacent normal mucosa even in the presence of GCV.
Yet, delivery of HSV-1(Gb) resulted in a high incidence of animal death signifying systemic viral toxicity. This toxicity was circumvented when systemic GCV was added to the treatment.
However, the treatment protocol combining HSV-1(Gb) and GCV mainly inhibited tumor progression rather than causing tumor regression or disappearance. When we used higher titers of HSV-1(Gb) to improve therapy, toxicity was evident despite GCV treatment (data not shown).
To further optimize the results achieved with HSVbased oncolysis in terms of efficacy and safety, we test the applicability of attenuated oncolytic HSV vectors in the orthotopic tumor model. HSV-1 vector, HSV-G47D, 9 is a third-generation vector with deletions of g34.5 and ICP47 genes, and an inactivating insertion of LacZ into ICP6. These genes are associated with neurovirulence, blocking major histocompatibility complex class I-mediated antigen presentation, and virus replication in nondividing cells. A potential drawback of this mutant is that replication is less efficient in tumor cells as compared to the wild-type virus. 9 Compared to treatment with HSV-1(Gb) and GCV, intratumoral HSV-G47D delivery alone was more efficient, resulting in tumor regression in the majority of Selective oncolytic activity of herpes simplex virus to colon carcinoma D Kolodkin-Gal et al mice. We assume the enhanced antitumor activity was achieved because viral replication was not suppressed by GCV. This assumption is in line with reports demonstrating that the therapeutic efficacy of GCV coadministered with oncolytic HSV vectors depends on the replicative ability of the vector. When the virus is replicative, the potential HSV-tk/GCV-mediated enhancement of oncolytic activity may be limited by the inhibitory action of GCV on viral replication. 17 HSV-G47D was not associated with in vivo toxicity, implying that it may be a safe vector for clinical use. However, the much larger tumor burden encountered in humans with rectal cancer compared to the mouse model poses additional obstacles to successful tumor eradication and will most probably require a widespread infection throughout the tumor tissue for effective oncolytic activity.
Although some tumor cells are impaired in their interferon (IFN) response pathways, 13 many tumors such as breast, melanoma, glioma, lung and colon carcinomas retain normal IFN response 15, 11, 18, 19 that may cause antiviral response, induced after viral infection. Thus, the oncolytic activity of viruses might be impaired in those tumors. Because the colon carcinoma cells CT26 are fully responsive to IFN, we reasoned that the oncolytic activity of HSV might be suppressed. The PKR pathway is known to be suppressed by the HSV1 g34.5 gene product that is deleted in HSV-G47D. 9 In fact, it has been previously shown that infection with attenuated HSV mutants (g34.5 deleted) resulted in PKR activation and consequently in virus inhibition. 13 To enhance the oncolytic activity of HSV-G47D, we coadministered the PKR inhibitor 2AP intratumor with the virus. Enhanced oncolytic activity was observed in vitro and in vivo after this combined treatment.
To the best of our knowledge, the concept of pharmacological inhibition of antiviral activity combined with the delivery of oncolytic viral vectors has not been previously reported. The proposed treatment is also suitable for oncolytic viruses other than herpes, such as VSV and NDV that strongly induce the IFN system and thus viral oncolytic activity is impaired by PKR. Further experimental effort should focus on issues related to intratumoral viral spread and on the interplay between oncolytic viruses and the antiviral activity of human tumors.
Materials and methods
Cells
Cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM), 10% fetal calf serum (FCS), 1% MEM Vitamin Solution (Biological industries, Beit Haemek, Israel), penicillin (100 U ml
À1
) and streptomycin sulfate (100 mg ml À1 ), at 37 1C in 5% CO 2 . Cell lines used in this work: Balb/C mouse colon carcinoma line CT26 encoding luciferase (CT26/luc), obtained from E Zeira, the Hebrew University; human colon carcinoma cell line Colo, human kidney cells 293T and monkey kidney Vero cells. HSV-G47D is a third-generation oncolytic HSV-1, mutant in ICP6, g34.5 and ICP47 and containing the LacZ gene at the ICP6 locus. 9 HSV-1 vectors were propagated in Vero cells and harvested from the cell pellet. Titer on Vero cells was determined using 0.5 mg ml À1 of human g-globulins 1 h after infection to block HSV spread, and 2 days after cells were stained with X-Gal and plaques counted.
Adenovirus Ad5CMVLacZ, a replication-defective virus containing the b-Gal gene under control of the immediate-early CMV promoter and deleted for the E1A gene, was propagated in 293T cells that express E1A. 21 Viruses were titered on Vero cells; 2 days after infection, cells were stained with X-Gal and the number of blue cells counted.
Lentiviral pseudotype vectors were produced by cotransfection of 293T cells, essentially as described previously, 22 using the packaging plasmid (pCMVDR8.9), a plasmid encoding the envelope VSV-G of vesicular stomatitis virus (pMDG) and a transfer plasmid pHR-NLS-LacZ, encoding b-Gal under the PGK promoter. Lentivirus was harvested at 48 and 72 h after transfection and filtered through 0.45-mm pore filters. Virus was titered on 293T cells; 23 2 days after infection, cells were stained with X-Gal and the number of blue cells counted.
All viruses were purified by sedimentation through a 10% sucrose cushion for 2 h at 4 1C. 23 The virus pellet was suspended in PBS and kept at À70 1C.
Tissues and organ cultures
Human colon cancer specimens and adjacent normal colonic mucosa were obtained immediately after surgical resection (under approval 20-01/08/03 of the Hadassah Hospital IRB committee). For preparation of organ cultures from mice orthotopic colon tumors, Balb/C mice (male 6-7 weeks old) were anesthetized with ketamine-xylazine and injected through the rectum into the colon mucosa and submucosa with colon carcinoma cells CT26/luc (2 Â 10 6 cells per 50 ml PBS), or s.c. into the low lateral side of the back. Orthotopic colon tumors developed usually after 3 weeks and s.c. tumors developed in 10 days. Mice were killed and the normal colon and adjacent tumor tissues were harvested and prepared for ex vivo organ culture. All animal experiments were conducted under approval of institution committee for animal care.
The organ culture medium was 'Supplemented Hormonal Epithelial Medium' (SHEM), 24 consisting of a 1:1 mixture DMEM and Ham's F12 with 5% FCS, 10 mM HEPES, 0.5% DMSO, 0.5 mg ml À1 hydrocortisone, 1% MEM Vitamin Solution (Biological industries), 5 mg ml À1 insulin, 5 mg ml À1 transferrin, 5 ng ml À1 selenium, 2 ng ml À1 epidermal growth factor, 100 mg ml À1 penicillin, 100 mg ml À1 streptomycin, 15 mg ml À1 gentamicin and 15 mg ml
À1
Ciproxin. Normal and tumor tissues of human and mouse origin were washed five times in SHEM (the normal mouse colon lumen was first opened with scissors), and tissues were cut in a microtome (Tissue Sectioner, TC-2; Sorvall Corp., Norwalk, CT, USA) into 500-mm-thick slices. Tissues were incubated at 37 1C, 5% CO 2 (5 slices per well in a 48-well plates) 8, 25 in SHEM. Organ culture tissues were infected with the viruses in 300 ml SHEM per well in a 48-well plate. At 2 h after infection, 5% FCS was added to the medium and tissues incubated for a further 22 h at 37 1C, 5% CO 2 .
8,25
Animal studies Mice were anesthetized with ketamine and xylazine then inoculated with CT26/luc cells (2 Â 10 6 cells per 100 ml PBS) into the colon (1 cm from the rectum into the mucin layer with 26-gauge syringe). After 9 days, when tumors developed, mice were injected directly to the tumor with the indicated viral vector. All animal experiments were conducted under approval of institution committee for animal care.
Imaging transgene expression in live animals
Ten minutes before monitoring of light emission, animals were anesthetized, and injected i.p. with luciferin in PBS (126 mg kg À1 body weight; Promega Corp., Madison, WI, USA). [26] [27] [28] The image was superimposed over the gray-scale mouse using CCD camera and analyzed by Meta Imaging Series 4.6. The composite image of a representative animal of each group is presented.
Histological analysis
For routine histological analysis, colon tissue was fixed in buffered formaldehyde (4%) and embedded in paraffin. Five-micrometer sections were stained with nuclear fast red (NFR) stain or hematoxylin and eosin (H&E).
For immunohistochemical detection of activated Caspase-3, formalin-fixed, paraffin-embedded colon tissues after X-Gal staining were cut (5 mm sections), deparaffinized in Histo-Clear (Finkelman Ltd. Chemicals, Petach Tikva, Israel), and rehydrated through a series of graded ethanol solutions. Tissue sections were incubated at 4 1C overnight in a humid chamber with the primary antibody, rabbit anti-activated Caspase-3 (Biocare Medical, Concord, CA, USA) diluted 1:200. Positive signal was detected with horseradish peroxidase (HRP)-conjugated secondary anti-rabbit IgG antibodies (Dako, Carpinteria, CA, USA). Sections were counterstained with hematoxylin.
X-Gal staining
Colon organ cultures were fixed for 10 min in 0.2% glutaraldehyde, 2% formaldehyde, 2 mM MgCl 2 in PBS (pH 7.4), washed in PBS and incubated for 1 h at 37 1C in X-Gal substrate (5-bromo-4-chloro-3-indolyl-b-Dgalactopyranoside), followed by fixation with 4% formaldehyde. 29 
Whole-mount immunofluorescence
Tissues were microtome-sectioned to 150-mm-thick slices and infected with the indicated viruses in 300 ml DMEM per well in a 48-well plate. At 2 h after infection, 5% FCS was added to the medium, and the infected tissues were incubated for further 72 h. The following protocol was carried out with minimal exposure to light. The tissues were fixed in 2% fresh paraformaldehyde for 15 min at room temperature, washed twice with PBS and stored in 70% ethanol at 4 1C. The tissues were transferred for 1 h to 50% methanol at room temperature, washed twice with PBS, permeabilized with 1% Triton X-100 in PBS for another hour, and blocked in Cas-Block (Zymed Laboratories, South San Francisco, CA, USA) for 2 h at room temperature. The primary antibodies were diluted in Selective oncolytic activity of herpes simplex virus to colon carcinoma D Kolodkin-Gal et al 0.5% Triton in Cas-Block and incubated at 4 1C overnight. The following primary antibodies were used: rabbit anti-activated Caspase-3 (Biocare Medical) diluted 1:200. The tissue sections were washed three times with 0.1% Tween 20 in PBS, and incubated overnight at 4 1C with a secondary antibody; Cy5-conjugated anti-rabbit (1:100) in 1% BSA in PBS. Tissue sections were washed three times with PBS and placed on a microscope slide with mounting buffer. All immunofluorescence images were captured with a Zeiss 510 confocal microscope.
Western blot analysis
Equal amounts of protein was subjected to SDS-PAGE on a 10% polyacrylamide gel and transferred to a nitrocellulose membrane (enhanced chemiluminescence, ECL; Amersham Pharmacia, Sunnyvale, CA, USA). The membrane with blotted protein was blocked for 1 h with 5% nonfat dry milk, followed by incubation with antibodies diluted as indicated in Tris-buffered saline (TBS-T) and 0.5% nonfat dry milk. For detection of total PKR, anti-PKR polyclonal antibody (catalog no. s.c.-1702; Santa Cruz, CA, USA) was diluted (1:200) and incubated for 1 h at room temperature. To detect the phosphorylated PKR, antiphospho-PKR monoclonal antibody (Abcam Corp., Cambridge, MA, USA) was diluted (1:1000) and incubated for 16 h at 4 1C. The membrane was washed three times with TBS-T for 15 min and incubated at room temperature for 1 h with diluted (1:10 000) secondary HRP-conjugated goat anti-rabbit IgG (Santa Cruz). Detection was carried out using the ECL Western Blotting Detection System and the intensity of the bands analyzed by a computer running an image-processing application (Gel capture and Tina-2.10).
Statistical analyses
All data are presented as means ± s.d. Statistical differences among groups were assessed with a two-tailed Student's t-test. A value of Po0.05 was considered significant and marked by an asterisk (*). A value of Po0.000001 was considered very significant and marked by two asterisks (**).
Kaplan-Meier survival analysis and Mantel-Cox logrank test were used for animal survival comparisons.
